Management of Juvenile idiopathic arthritis-associated uveitis duringthe COVID-19 pandemic in a pediatric referral center in Lombardy

Ocul Immunol Inflamm. 2020 Nov 16;28(8):1305-1307. doi: 10.1080/09273948.2020.1800752. Epub 2020 Sep 25.


Italy was the first European country to be affected by the SARS-CoV-2 pandemic. In this scenario, we had to face a new clinical approach in our Pediatric Rheumatology Unit for the management of patients affected by juvenile idiopathic arthritis (JIA)-associated uveitis. During the lockdown (phase 1), the weekly outpatient clinic was discontinued and telephone consultations were set up. A toll-free telephone number was instituted for emergencies. None of our children with JIA-associated uveitis was advised to stop the ongoing immunosuppressant systemic therapy. We had no cases of COVID-19 infection and uveitis activity was under control in all but two out of 125 patients, which was comparable with the pre-COVID-19 situation. During phase 2 of the pandemic, hospital and ambulatory rearrangements were made to minimize the risk of SARS-CoV-2 infection. Overall, during the first 4 weeks of phase 2, we did not notice an increased number of patients with uveitis activity.

Keywords: COVID-19; JIA-associated uveitis; SARS-CoV-2; juvenile idiopathic arthritis; pediatric uveitis.

Publication types

  • Review

MeSH terms

  • Arthritis, Juvenile / complications*
  • Betacoronavirus*
  • COVID-19
  • Child
  • Coronavirus Infections / epidemiology*
  • Disease Management*
  • Humans
  • Italy / epidemiology
  • Pandemics
  • Pneumonia, Viral / epidemiology*
  • Referral and Consultation*
  • SARS-CoV-2
  • Uveitis / etiology
  • Uveitis / therapy*